Oxxon Therapeutics Inc. Announces The Promotion Of Dr. Mark Payton To Vice President Of Corporate Development
10/19/2005 5:10:58 PM
BOSTON--(BUSINESS WIRE)--April 26, 2005--Oxxon Therapeutics, Inc. (Oxxon) announced today that Dr. Mark Payton has been promoted to vice president of corporate development at the Company. The promotion of Dr. Payton is part of the Company's increased effort to develop and strengthen its partnering and commercialization team. Oxxon is a biotechnology company developing immunotherapeutics for cancer and chronic infectious diseases.
"Mark has made significant contributions to the Company since joining us in 2001 as business development manager," said Dr. Deirdre Gillespie, president and chief executive officer of Oxxon. "He will continue to be a key part of our growth as we advance our pipeline and focus increasingly on partnering agreements, such as our recent in-licensing agreement with Xenova that Mark helped broker."
comments powered by